UNSPSC 51411614: Dilevalol hydrochloride

This classification denotes a vasodilating agent and adrenergic antagonist with the molecular structure C19H24N2O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, O5OBT75D2C chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-, monohydrochloride, (r-(r*,r*))-, but more commonly known as dilevalol hydrochloride, which bears US NIH Compound Identifier 636407.

European Medicines Agency schedules Dilevalol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01734MIG. Most nations, for tariff and trade purposes, schedule dilevalol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, DILEVALOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@H](CCC1CCCCC1)NC[C@@H](C2CCC(C(C2)C(=O)N)O)O.CL.

UNSPSC 51411614 Dilevalol hydrochloride is a Commodity code covering prescription medications supplied to state and local emergency medical and healthcare systems. State and local governments procure this and related advanced life support medications for fire rescue departments, emergency medical services, and public health agencies through sealed-bid purchases and cooperative-purchasing arrangements. The work involves supplying medications in specified quantities with strict expiration-date and shelf-life requirements, arranging timely delivery and replacement logistics, and providing comprehensive compliance documentation including Safety Data Sheets and accessibility reports. Issuing bodies include municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances representing dozens of state and local health facilities. Small local business enterprise set-asides appear in municipal procurements, while state-level cooperative vehicles often carry no formal set-aside designations but require cGMP certification and Drug Supply Chain Security Act compliance.

Recent activity spans Florida, Texas, and Minnesota with interstate cooperative purchasing. The City of Tampa's Purchasing Department posted an IFB (Solicitation 26P00188) on April 24, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem—due April 8, 2026, with estimated contract value of $40,000—for use by Tampa Fire Rescue in Hillsborough County. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting self-insured employers and state agencies, with no award value specified at the preliminary information-gathering stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, contract effectiveness July 1, 2026, and pricing weighted at 75 percent of evaluation criteria.